Meanwhile, the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) announced on Wednesday that it is probing a cybersecurity breach involving a standalone system. Distinguished as a “major incident” under federal standards, this development has captured the attention of senior Justice Department officials.

This revelation surfaces as the Qilin ransomware group claims responsibility for targeting the ATF, according to cybersecurity analysts monitoring the group’s online activity. Although Qilin has yet to furnish evidence to back up its assertion, the ATF has not attributed the breach to this particular group.

The ATF has clarified that the compromised system functions independently of its main network. Investigations suggest that neither the agency’s broader network, its eForms system, nor any other ATF platforms have been impacted by this breach.

Upon uncovering the incident, the ATF swiftly isolated the affected environment and initiated thorough forensic and incident-response procedures. The bureau is working in conjunction with the Justice Department to dissect the details of this security lapse.

The agency did not identify the affected system, say when the incident was discovered or disclose whether any data was accessed or stolen.

Cybernews reported Wednesday that Qilin claimed ATF as its latest victim but had provided no evidence or details supporting the claim. 

GalaxyWarden, a breach-monitoring service, separately reported that ATF appeared on Qilin’s leak site and that the group claimed it obtained files from the agency. GalaxyWarden said it had not independently verified the group’s assertions.

News Media reached out to ATF and the Justice Department for additional information, including whether officials believe Qilin was responsible for the incident, whether any data was accessed or stolen and what prompted officials to designate the event a “major incident.”

ATF said senior Justice Department officials designated the cybersecurity event a “major incident” under applicable federal guidelines and that required notifications have been completed.

DOJ CHARGES 3 RUSSIANS IN ALLEGED $63M CYBERCRIME SCHEME TARGETING AMERICANS

The incident has not disrupted ATF operations or affected the agency’s ability to carry out its missions, according to the agency.

The agency asked anyone with information related to the incident to contact the ATF Tipline at 1-888-ATF-TIPS, or 1-888-283-8477.

In a significant medical breakthrough, the U.S. Food and Drug Administration (FDA) has granted approval to a new drug poised to enhance survival rates for individuals battling metastatic pancreatic cancer.

Revolution Medicines will market the drug as Rasonque, with its scientific designation of daraxonrasib. This innovative daily medication is designed to target the RAS protein family, notorious for its role in fueling tumor growth.

In an extensive clinical trial involving 500 participants, results were compelling. The median overall survival time for patients nearly doubled, reaching over 13 months, compared to about 6.7 months with traditional chemotherapy.

Dr. Brian Wolpin, head of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, expressed the significance of this approval in a statement to ABC News, highlighting it as a landmark achievement born from years of dedication to targeting the KRAS pathway.

“This approval presents a novel treatment avenue and renewed hope for those suffering from metastatic pancreatic cancer,” Dr. Wolpin remarked, emphasizing that the breakthrough forms a vital foundation for further advances against one of the most challenging cancers known today.

About 95% of exocrine pancreatic cancers in the U.S. are pancreatic adenocarcinoma, according to the American Cancer Society.

Although pancreatic adenocarcinoma represents only about 3.2% of all cancer diagnoses, it accounts for a disproportionately high share of cancer deaths, according to the FDA.

This is due to several factors including late detection, aggressive disease course and historically limited treatment options, the federal health agency said.

In June 2025, the FDA granted the drug a “Breakthrough Therapy” designation. This allows for expedited development and review of drugs that treat serious conditions and have preliminary evidence showing substantial improvement over available treatments.

The application was reviewed under the Commissioner’s National Priority Voucher Program, initiated by former FDA Commissioner Dr. Marty Makary. The review time was accelerated from 12 months to 10 months.

There is hope that this new type of targeted treatment will show benefits for other hard-to-treat cancers.

“This drug showed unprecedented results in an area of high unmet need,” Dr. Angelo de Claro, director of the FDA’s Oncology Center of Excellence, said in a press release. “The approval was granted 6.5 months before the user fee deadline, demonstrating the FDA’s commitment to accelerating the approval of new cancer treatments for patients with serious and life-threatening conditions.”

The FDA approval was granted for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or cancer treatments that target the entire body. Other drug candidates also include those getting multiagent systemic therapy, meaning two or more treatments.

Patients who participated in the clinical trial told “Good Morning America” in June that the drug renewed optimism about their prognoses.

One patient named Jim said that after beginning treatment with daraxonrasib, a tumor in his liver that had spread from his pancreas shrank significantly.

“The tumor that I had in my liver, which had spread from the pancreas, got reduced by 50%, which was incredible news,” he told “GMA.”

This season, the Golden State Warriors will pay tribute to legendary NBA coach Don Nelson by wearing a commemorative patch on their uniforms. The patch will feature the word “NELLIE” across the shoulder, a heartfelt nod to their former coach.

On Wednesday, Golden State revealed plans for the tribute patch to honor Nelson, who passed away on August 9.

Nelson’s coaching legacy with the Warriors is notable, encompassing two distinct periods from 1988-1995 and 2006-2010, during which he secured 422 regular-season wins with the team.

Under his leadership, the Warriors made significant strides, reaching the playoffs six times and advancing to the Western Conference finals on three occasions.

Before his successful time with Golden State, Nelson had a remarkable career with the Milwaukee Bucks, achieving a 540-344 record from November 1976 through May 1987.

In 2010, Nelson became the NBA’s all-time winningest coach and eventually fell to second on that list in 2022, when Gregg Popovich surpassed him. Nelson had 1,335 regular-season victories, and Popovich had 1,390.

Although Nelson never won an NBA Finals, one of his most iconic moments as a coach came in 2007 when he sparked his Golden State team with “We believe.” The Warriors eliminated a 67-win Mavericks team from the playoffs and became the first eighth-seeded team to eliminate a top-seeded team in a seven-game playoff series.

The game differential of the Warriors over the Mavericks went on to become the largest by a team to do so in a playoff series.

Nelson’s final major contribution to the Warriors came in 2009, when he laid the foundation for the franchise’s dynasty.

At the time, it was viewed as a “long shot,” but the Warriors selected Steph Curry with the seventh overall pick of the 2009 NBA Draft based on Nelson’s recommendation. The franchise went on to win four NBA titles in 2015, 2018, 2018 and 2022 behind the game’s greatest shooter.